Trial reportPediatrics2017
Metformin for Obesity in Prepubertal and Pubertal Children: A Randomized Controlled Trial.
Trial report in Pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Pooled it
- Pooled it
- Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial.Pediatric obesity · 2021Trial
- Trial
- Systematic review of influence of ethnicity on efficacy and safety of pharmacotherapy for childhood and adolescent obesity.Clinical and experimental pediatrics · 2026Article
- Review of Hyperbaric Oxygen Therapy as an Adjunctive Intervention for Metabolic Disorders.Antioxidants (Basel, Switzerland) · 2025Review
- A Systemic Review of Pharmacological Management of Pediatric Obesity.Journal of pharmacy & bioallied sciences · 2025Review
- A New Strategy for Obesity Treatment: Revealing the Frontiers of Anti-obesity Medications.Current molecular medicine · 2025Review
- Special considerations for the child with obesity: An Obesity Medicine Association (OMA) clinical practice statement (CPS) 2024.Obesity pillars · 2024Article
- Article
- Metformin reduces insulin resistance and attenuates progressive renal injury in prepubertal obese Dahl salt-sensitive rats.American journal of physiology. Renal physiology · 2023Article
- Metformin Can Attenuate Beta-Cell Hypersecretion-Implications for Treatment of Children with Obesity.Metabolites · 2023Article
- Lifestyle and Pharmacological Interventions and Treatment Indications for the Management of Obesity in Children and Adolescents.Children (Basel, Switzerland) · 2023Review
- Anti-Obesity Effects of Metformin: A Scoping Review Evaluating the Feasibility of Brown Adipose Tissue as a Therapeutic Target.International journal of molecular sciences · 2023Article
- Metformin therapy in pediatric type 2 diabetes mellitus and its comorbidities: A review.Frontiers in endocrinology · 2022Review
- Metformin: Activation of 5' AMP-activated protein kinase and its emerging potential beyond anti-hyperglycemic action.Frontiers in genetics · 2022Review
- Metformin for Cardiovascular Protection, Inflammatory Bowel Disease, Osteoporosis, Periodontitis, Polycystic Ovarian Syndrome, Neurodegeneration, Cancer, Inflammation and Senescence: What Is Next?ACS pharmacology & translational science · 2021Review
- Adolescent obesity treatments: news, views, and evidence.Archives of endocrinology and metabolism · 2021Review
- Erectile Dysfunction Is a Hallmark of Cardiovascular Disease: Unavoidable Matter of Fact or Opportunity to Improve Men's Health?Journal of clinical medicine · 2021Review
- Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
- Erratum issued
Authors and funding
13 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMetformin has shown its effectiveness in treating obesity in adults. However, little research has been conducted in children, with a lack of attention on pubertal status. The objectives were to determine whether oral metformin treatment reduces BMI
methodsThis was a randomized, prospective, double-blind, placebo-controlled, multicenter trial, stratified according to pubertal stage and sex, conducted at 4 Spanish clinical hospitals. Eighty prepubertal and 80 pubertal nondiabetic children who were obese aged 7 to 14 years with a BMI >95th percentiles were recruited. The intervention included 1 g/d of metformin versus placebo for 6 months. The primary outcome was a reduction in BMI
resultsA total of 140 children completed the study (72 boys). Metformin decreased the BMI
conclusions“Metformin decreased the BMI z score and improved inflammatory and cardiovascular-related obesity parameters only in prepubertal children, but a differential effect of metformin was not observed in prepubertal compared to pubertal children. Nevertheless, the doses per kilogram of weight administrated may have had an impact on the metformin effect. Further investigations are necessary.”
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.